Journal article
Cardiovascular effects of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Abstract
BackgroundConcerns about the cardiovascular safety of incretin-based therapies, which include dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, in patients with type 2 diabetes have been raised. We aimed to systematically assess the cardiovascular effects of incretin-based therapies in patients with type 2 diabetes.MethodsIn this systematic review and network meta-analysis, we searched MEDLINE, Embase, the …
Authors
Wu S; Yang J; Cai T; Xu Y; Yang Z; Zhang Y; Chai S; Sun F; Zhan S
Journal
The Lancet Diabetes & Endocrinology, Vol. 4, ,
Publisher
Elsevier
Publication Date
November 2016
DOI
10.1016/s2213-8587(16)30373-4
ISSN
2213-8587